Russian Direct Investment Fund (RDIF), a sovereign wealth fund in Russia has allied Dr Reddy’s Laboratories (DRL), the Hyderabad-based drug manufacturer to cooperate on clinical trials and distribution of Sputnik V vaccine in India. This arrangement claims to deliver the vaccine for general use probably beginning late 2020. After obtaining regulatory approvals from DCGI (Drug Controller General of India) for conducting trials in India, DRL will receive 100 million doses of the Covid19 vaccine — developed by the Gemaleya National Center of Epidemiology and Microbiology (Moscow, Russia). The results of the early phases (Phase 1 and 2) of trials with the vaccine were recently published in Lancet in September 2020, while both India and Russia were laying the groundwork to pursue further trials and production of the vaccine in India. The Indian Council of Medical Research (ICMR) expresses that Russia has a good track record in development of vaccines. Sputnik V is based on ...